Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2021 01/21/2021 01/22/2021 01/25/2021 01/26/2021 Date
67.99(c) 66.98(c) 66.94(c) 68.16(c) 66.7 Last
10 131 253 8 145 642 4 914 433 8 443 926 7 113 864 Volume
+1.37% -1.49% -0.06% +1.82% -2.14% Change
More quotes
Financials (USD)
Sales 2020 24 348 M - -
Net income 2020 137 M - -
Net Debt 2020 24 871 M - -
P/E ratio 2020 1 197x
Yield 2020 3,97%
Sales 2021 24 443 M - -
Net income 2021 7 556 M - -
Net Debt 2021 20 836 M - -
P/E ratio 2021 11,1x
Yield 2021 4,13%
Capitalization 85 440 M 85 440 M -
EV / Sales 2020 4,53x
EV / Sales 2021 4,35x
Nbr of Employees 11 800
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.5%): especially royalties and... 
More about the company
Notations Surperformance© of Gilead Sciences, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about GILEAD SCIENCES, INC.
01/25MARKET CHATTER : Daewoong Pharmaceutical to Start Phase 3 Trial for COVID-19 Dru..
MT
01/25INSIDER TRENDS : Insider at Gilead Sciences Reports Option Conversion in Mist of..
MT
01/21GILEAD SCIENCES : to Release Fourth Quarter and Full Year 2020 Financial Results..
BU
01/20GILEAD SCIENCES : Company - Francesco M. Marincola Joins Kite as Worldwide Head ..
AQ
01/19Gilead Sciences Up Nearly 7%, Best Performer in the Nasdaq 100 So Far Today -..
DJ
01/19STREET COLOR : SCOTUS Refuses to Hear Merck's Bid to Revive $2.5 Bln Patent Infr..
MT
01/19GILEAD SCIENCES : U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent ..
RE
01/19U.s. supreme court refuses to hear merck & co bid to revive $2.5 billion pate..
RE
01/19GILEAD SCIENCES : U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent ..
RE
01/19GILEAD SCIENCES : Francesco M. Marincola Joins Kite as Worldwide Head of Cell Th..
BU
01/19GILEAD SCIENCES : Morgan Stanley Upgrades Gilead Sciences to Overweight From Equ..
MT
01/19GILEAD SCIENCES, INC. : Nomination
CO
01/15STRIDES PHARMA SCIENCE : Arm Gets US FDA Nod for HIV/AIDS Treatment Drug
MT
01/13GILEAD SCIENCES : Statement on Recent Events in Washington, D.C.
PU
01/12INSIDER TRENDS : Bridge Bancorp Insider Receives Stock Award, Buy Trend Intact
MT
More news
News in other languages on GILEAD SCIENCES, INC.
01/19WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
01/11Wall Street souffle après des records
01/11MÄRKTE USA/Leichte Gewinnmitnahmen belasten Börsen
01/11Wall Street ouvre en baisse après des records
01/11MÄRKTE USA/Wall Street von Gewinnmitnahmen belastet
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 72,89 $
Last Close Price 68,16 $
Spread / Highest target 46,7%
Spread / Average Target 6,94%
Spread / Lowest Target -14,9%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.16.99%85 440
WUXI APPTEC CO., LTD.36.65%68 869
VERTEX PHARMACEUTICALS2.10%62 750
REGENERON PHARMACEUTICALS13.47%57 859
BEIGENE, LTD.45.87%34 368
GENMAB A/S6.17%27 892